Search results
Results from the WOW.Com Content Network
Neonatal alloimmune thrombocytopenia (NAITP, NAIT, NATP or NAT) is a disease that affects babies in which the platelet count is decreased because the mother's immune system attacks her fetus' or newborn's platelets. A low platelet count increases the risk of bleeding in the fetus and newborn.
One common definition of thrombocytopenia requiring emergency treatment is a platelet count below 50,000/μL. [5] Thrombocytopenia can be contrasted with the conditions associated with an abnormally high level of platelets in the blood – thrombocythemia (when the cause is unknown), and thrombocytosis (when the cause is known). [6] [7]
In addition to identifying a core list of disorders that infants in the United States should be screened for, the ACMG also established a framework for nominating future conditions, and the structure under which those conditions should be considered. Severe combined immune deficiency (SCID) - added in 2009 [3]
The differential diagnosis for Congenital amegakaryocytic thrombocytopenia includes thrombocytopenia-absent radius syndrome and Wiskott-Aldrich syndrome. Congenital amegakaryocytic thrombocytopenia is distinguished from thrombocytopenia-absent radius syndrome on the basis of skeletal hypoplasia in the arms.
The risk of neonatal thrombocytopenia is increased with: [66] Mothers with a history of splenectomy for ITP; Mothers who had a previous infant affected with ITP; Gestational (maternal) platelet count less than 100,000/uL; It is recommended that pregnant women with thrombocytopenia or a previous diagnosis of ITP be tested for serum antiplatelet ...
This is an incomplete list, which may never be able to satisfy certain standards for completion. There are many conditions of or affecting the human hematologic system—the biological system that includes plasma, platelets, leukocytes, and erythrocytes, the major components of blood and the bone marrow. [1]
Consequently, differential diagnosis of these TMA diseases is essential. Both TTP and HUS are characterized by fever, anemia, thrombocytopenia, renal failure, and neurological symptoms. Generally, TTP has higher rates of neurological symptoms (≤80%) and lower rates of renal symptoms (9%) than HUS (10–20% and 90%, respectively). [38]
Kasabach–Merritt syndrome (KMS), also known as hemangioma with thrombocytopenia, [1] is a rare disease, usually of infants, in which a vascular tumor leads to decreased platelet counts and sometimes other bleeding problems, [2] which can be life-threatening. [3] It is also known as hemangioma thrombocytopenia syndrome.